Drug-Induced Thrombocytopenia in ICU Patients

Primary Drug Culprits

Heparin is the most critical drug-induced cause of thrombocytopenia in the ICU, requiring immediate recognition and management due to its paradoxical thrombotic risk, with unfractionated heparin carrying a 10-fold higher risk of heparin-induced thrombocytopenia (HIT) compared to low molecular weight heparin (LMWH) 1, 2, 3, 4
Women have approximately twice the risk of developing HIT compared to men, with cardiac surgery patients receiving unfractionated heparin having the highest risk (1-5%) 3, 4
GPIIb-IIIa glycoprotein inhibitors cause early and often profound thrombocytopenia in acute coronary syndrome patients 1, 2
Antimitotic chemotherapies directly suppress platelet production, leading to thrombocytopenia through bone marrow suppression 1, 2

Perioperative hemodilution from massive fluid resuscitation causes dilutional thrombocytopenia, particularly common after major vascular or cardiac surgery 1, 2
Extracorporeal circuits and intra-aortic balloon pumps cause consumption thrombocytopenia through platelet activation and destruction 1, 2, 6
Post-transfusion purpura presents with sudden, major platelet drops and hemorrhagic manifestations, requiring urgent recognition due to severe bleeding risk 1, 2
Antiphospholipid syndrome can present with both thrombocytopenia AND thrombosis, mimicking HIT 1, 2

When thrombocytopenia develops in a heparinized ICU patient, immediately calculate the 4T score to assess HIT probability before considering other drug causes 1, 6
A 4T score of 6-8 indicates high probability, 4-5 intermediate probability, and 0-3 low probability of HIT 1, 6

Stop ALL heparin immediately and initiate therapeutic-dose alternative anticoagulation even without confirmed thrombosis, as 30-50% of untreated HIT patients develop thrombosis within 30 days 6
Never use prophylactic doses of alternative anticoagulants—therapeutic doses are mandatory even in isolated HIT without documented thrombosis 6
Do not initiate warfarin until platelet count recovers to >150 × 10⁹/L, as early warfarin use can cause venous limb gangrene 6

For normal renal and hepatic function, argatroban, bivalirudin, fondaparinux, or DOACs are appropriate alternatives; for severe renal impairment (CrCl <30 mL/min), argatroban is the only recommended agent 6
Argatroban is contraindicated in severe hepatic impairment (Child-Pugh C) 6
Monitor argatroban by targeting aPTT 1.5-3 times baseline, checking aPTT 2 hours after dose initiation or adjustment 6